BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Industry & Community · 26 Sep 2026
Same Day, Different Strategies: How Lilly's $6.5 Billion Houston Groundbreaking and Novo's Capital Markets Day Reveal Diverging Paths in the Oral GLP-1 Manufacturing Race
On 21 September 2026, Eli Lilly broke ground on a $6.5 billion API facility in Houston and Novo Nordisk hosted its Capital Markets Day in London, where it pledged to scale oral GLP-1 manufacturing tenfold by 2030. The two announcements — made on the same day — illuminate fundamentally different production strategies and have direct implications for the peptide supply chain.
Read briefing →
Research Pipeline
Beyond Semaglutide and Tirzepatide: What a September 2026 Systematic Review Reveals About the Next Wave of GLP-1 Peptide Candidates
A systematic review published in the Annals of Internal Medicine on 18 September 2026 consolidates placebo-subtracted weight-loss data across 38 randomised controlled trials and 25,816 participants, offering the clearest cross-compound comparison to date. The findings contextualise where approved agents stand and how emerging multi-agonist peptides — retatrutide, amycretin, and a crop of oral candidates — are reshaping the development landscape.
25 Sep 2026
Regulatory & Policy
Two Months After the PCAC Vote: Where BPC-157, TB-500, Semax and Three Other Peptides Stand on the Road to the 503A Bulks List
The FDA's Pharmacy Compounding Advisory Committee recommended six peptides for 503A inclusion in July 2026 — but the votes were non-binding, FDA staff opposed all seven, and formal rulemaking has not yet begun. This briefing maps the full regulatory journey still ahead and what it means for procurement professionals today.
24 Sep 2026
Research Pipeline
Thymosin Alpha-1 (Zadaxin): The Thymic Peptide With Genuine Clinical Approval in 35 Countries, a Contested US Compounding Status, and No MHRA Licence
Thymosin alpha-1 (Tα1) is a 28-amino-acid thymic peptide approved as Zadaxin in more than 35 countries for chronic hepatitis B, yet it holds no FDA approval in the United States and no MHRA marketing authorisation in the United Kingdom. This briefing sets out its mechanism, the state of clinical evidence across hepatitis, sepsis and oncology indications, and the US compounding regulatory position following the February 2026 reclassification.
23 Sep 2026
Reputational Risks
FDA's September 2026 Peptide Vendor Sweep: Five Warning Letters, the "Research-Use Only" Labelling Test, and What It Means for Legitimate Suppliers
On 1 September 2026, the FDA published five simultaneous warning letters to online peptide sellers, citing the illegal marketing of injectable semaglutide, tirzepatide, retatrutide, tesamorelin and other unapproved compounds. The sweep expands an established enforcement pattern and clarifies how regulators assess "research-use only" claims — with direct implications for compliant research-grade suppliers in the UK and US.
22 Sep 2026
Industry & Community
The Oral Peptide Delivery Race: Approvals, Formulation Science, and the Investment Wave Reshaping Drug Development in 2026
A cluster of FDA approvals, landmark partnership deals, and oversubscribed financing rounds in 2026 signals that oral delivery of peptide therapeutics is transitioning from a persistent scientific aspiration to a commercially credible drug class. Research-procurement teams sourcing peptide APIs and formulation materials need to understand the technical and market forces now driving this shift.
21 Sep 2026
Regulatory & Policy
Eight Days Left: FDA's 17 Revised Draft Peptide Guidances and What the Withdrawn 2021 Framework Means for Generic Developers
The FDA published 17 revised draft product-specific guidances for generic peptide products on 28 July 2026, covering semaglutide, tirzepatide, liraglutide, teriparatide and 13 other reference drugs. The public comment window closes on 28 September 2026 — eight days from today. The agency simultaneously withdrew its May 2021 synthetic-peptide guidance, leaving sponsors mid-programme without a replacement framework until later in 2026.
20 Sep 2026
Research Pipeline
Peptide-Drug Conjugates Move Closer to the Clinic: TwoStep Therapeutics' FDA IND Clearance and the Emerging PDC Landscape
TwoStep Therapeutics secured FDA clearance of its IND for TS-104 — a multi-specific peptide-drug conjugate targeting five tumour-associated integrins — alongside a $62.5 million Series A in September 2026. The milestone sits within a broader surge of investment and clinical activity in peptide-drug conjugates, a modality attracting attention as a lower-cost, better-penetrating alternative to antibody-drug conjugates.
19 Sep 2026
Pharma & GLP-1
Novo Nordisk and Orbis Medicines Sign Up-to-$1.4 Billion Oral Macrocyclic Peptide Pact for Cardiometabolic Disease
Novo Nordisk has entered a discovery and licensing collaboration with Orbis Medicines worth up to $1.4 billion to develop oral macrocyclic peptides for cardiometabolic conditions currently dominated by injectable drugs. The deal, reported by Reuters on 17 September 2026, signals Novo's intent to extend its oral-drug ambitions beyond semaglutide into a structurally distinct molecule class.
18 Sep 2026
Reputational Risks
Three Texas Recalls in Six Weeks: How Dietary-Grade Glutathione API Triggered a Compounding Safety Crisis — and What State Boards Are Now Saying About Research-Grade Peptides
Three Texas compounding pharmacies recalled injectable glutathione products between August and September 2026 after elevated bacterial endotoxin levels were traced to a shared dietary-supplement-grade API source. With at least 39 adverse events on record, the episode illustrates a recurring quality failure the FDA first warned about in 2019. Separately, Mississippi and South Carolina issued near-identical joint statements in August 2026 barring licensed providers from compounding…
17 Sep 2026
Pharma & GLP-1
Lilly's EASD 2026 Disclosures: TRIUMPH-2 Phase 3 Retatrutide Data, ACHIEVE-4 Foundayo Cardiovascular Findings, and a First Look at eloraTZP Phase 2
Eli Lilly published its pre-EASD data package on 15 September 2026, confirming Phase 3 TRIUMPH-2 results for the investigational triple agonist retatrutide, Phase 3 ACHIEVE-4 cardiovascular data for orforglipron (Foundayo), and a forthcoming Phase 2 readout for eloraTZP — a combination of eloralintide and tirzepatide. The disclosures arrive against a backdrop of active illicit-market enforcement, with a regulatory filing for retatrutide expected before year-end.
16 Sep 2026
Industry & Community
Samsung Biologics' PolyPeptide Tender Window Opens Today: What the CHF 1.46 Billion Bid Means for Peptide API Supply
The formal acceptance period for Samsung Biologics' all-cash offer to acquire PolyPeptide Group opened on 15 September 2026, running until 12 October. With PolyPeptide's largest shareholder already committed to tender its 55.65% stake, completion appears probable — reshaping who controls a significant share of globally validated solid-phase peptide synthesis capacity.
15 Sep 2026